Immune modulation therapy-graft-versus-host disease - Vasogen

Drug Profile

Immune modulation therapy-graft-versus-host disease - Vasogen

Alternative Names: VAS 981

Latest Information Update: 23 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vasogen
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Graft-versus-host disease

Most Recent Events

  • 07 Jan 2004 No development reported - Preclinical for Graft-versus-host disease in Canada (unspecified route)
  • 31 Mar 2000 Health Canada has given approval for initiation of a clinical trial in patients with leukaemia
  • 23 Aug 1999 Preclinical development for Graft-versus-host disease in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top